Noxafil(posaconazole)
Noxafil, Posaconazole (posaconazole) is a small molecule pharmaceutical. Posaconazole was first approved as Noxafil on 2005-10-25. It is used to treat mycoses and oral candidiasis in the USA. It has been approved in Europe to treat aspergillosis, candidiasis, coccidioidomycosis, and mycoses.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| stomatognathic diseases | D009057 |
Trade Name
FDA
EMA
Noxafil, Posaconazole (discontinued: Noxafil, Posaconazole)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Posaconazole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NOXAFIL | Merck & Co | N-205596 RX | 2014-03-13 | 1 products, RLD, RS |
| NOXAFIL POWDERMIX KIT | Merck & Co | N-214770 RX | 2021-05-31 | 1 products, RLD, RS |
| NOXAFIL | Merck & Co | N-022003 RX | 2006-09-15 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| noxafil | New Drug Application | 2024-10-25 |
| posaconazole | ANDA | 2025-06-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| mycoses | — | D009181 | B35-B49 |
| oral candidiasis | EFO_0007406 | D002180 | B37.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
POSACONAZOLE, NOXAFIL, MERCK SHARP DOHME | |||
| 2028-06-17 | ODE-355 | ||
| 2024-06-17 | I-881 | ||
| 2024-05-31 | NPP | ||
POSACONAZOLE, NOXAFIL POWDERMIX KIT, MSD MERCK CO | |||
| 2024-05-31 | NP | ||
HCPCS
No data
Clinical
Clinical Trials
105 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mycoses | D009181 | — | B35-B49 | 7 | 8 | 10 | 7 | 12 | 44 |
| Invasive fungal infections | D000072742 | — | — | 4 | 3 | 7 | 5 | 7 | 26 |
| Infections | D007239 | EFO_0000544 | — | 5 | 5 | 6 | 4 | 5 | 24 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 8 | 9 | 1 | 4 | 4 | 20 |
| Leukemia | D007938 | — | C95 | 7 | 10 | — | 1 | 4 | 17 |
| Myeloid leukemia | D007951 | — | C92 | 5 | 8 | 1 | 3 | 4 | 17 |
| Communicable diseases | D003141 | — | — | 5 | 1 | 3 | 2 | 4 | 15 |
| Aspergillosis | D001228 | EFO_0007157 | B44 | 1 | 2 | 4 | 2 | 4 | 12 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | 4 | 1 | 3 | 1 | 9 |
| Invasive pulmonary aspergillosis | D055744 | — | B44.0 | 1 | 1 | 2 | 1 | 2 | 7 |
Show 17 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 3 | 2 | 1 | — | — | 5 |
| Invasive hydatidiform mole | D002820 | — | D39.2 | — | — | 1 | — | 3 | 4 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 1 | 1 | — | — | 3 |
| Fibrosis | D005355 | — | — | — | 1 | 1 | — | 1 | 2 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 1 | 1 | — | 1 | 2 |
| Chronic granulomatous disease | D006105 | EFO_0000338 | D71 | — | 1 | 1 | — | — | 2 |
| Oral candidiasis | D002180 | EFO_0007406 | B37.0 | — | 1 | 1 | — | — | 2 |
| Candidemia | D058387 | EFO_1001282 | — | — | — | 1 | — | — | 1 |
| Fungemia | D016469 | — | B49 | — | — | 1 | — | — | 1 |
| Pneumocystis pneumonia | D011020 | EFO_0007448 | B59 | — | — | 1 | — | — | 1 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | 2 | — | — | — | 2 |
| Lymphoma | D008223 | — | C85.9 | 1 | 1 | — | — | — | 2 |
| Onychomycosis | D014009 | — | B35.1 | — | 1 | — | — | 1 | 2 |
| Chagas disease | D014355 | EFO_0008559 | B57 | — | 2 | — | — | — | 2 |
| Mucormycosis | D009091 | EFO_0007380 | B46.5 | — | 1 | — | — | 1 | 2 |
| Zygomycosis | D020096 | — | B46 | — | 1 | — | — | 1 | 2 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | — | 1 | 1 | — | — | — | 1 |
| Virus diseases | D014777 | — | B34 | — | 1 | — | — | — | 1 |
| Respiratory syncytial virus infections | D018357 | EFO_1001413 | — | — | 1 | — | — | — | 1 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | 1 | — | — | — | 1 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | 1 | 2 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 1 | — | — | — | — | 1 |
| Recurrence | D012008 | — | — | 1 | — | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 3 | 3 |
| Critical illness | D016638 | — | — | — | — | — | — | 2 | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
| Fungal lung diseases | D008172 | EFO_0007278 | — | — | — | — | — | 1 | 1 |
| Genetic predisposition to disease | D020022 | — | — | — | — | — | — | 1 | 1 |
| Fusariosis | D060585 | EFO_1001795 | — | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Mucositis | D052016 | EFO_1001898 | — | — | — | — | — | 1 | 1 |
| Lung transplantation | D016040 | — | — | — | — | — | — | 1 | 1 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Posaconazole |
| INN | posaconazole |
| Description | Posaconazole, sold under the brand name Noxafil among others, is a triazole antifungal medication.
|
| Classification | Small molecule |
| Drug class | systemic antifungals (miconazole type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O |
Identifiers
| PDB | — |
| CAS-ID | 171228-49-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1397 |
| ChEBI ID | 64355 |
| PubChem CID | 147912 |
| DrugBank | DB01263 |
| UNII ID | 6TK1G07BHZ (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Noxafil – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Posaconazole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 12,569 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,815 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use